Answers are grounded in this paper and cite their sources.
The experimental approach finds that enhancing METTL3 S-palmitoylation improves cartilage integrity in osteoarthritis, suggesting a new therapeutic strategy.
• ZDHHC24 and ABHD17A control reversible S-palmitoylation of METTL3 • Mettl3 C376S mice show impaired cartilage development and aggravated osteoarthritis • Isoborneol restores METTL3 S-palmitoylation and improves osteoarthritic phenotypes in vivo • S-palmitoylation drives METTL3 phase separation, translation, and protein stability ZDHHC24 and ABHD17A control reversible S-palmitoylation of METTL3 Mettl3 C376S mice show impaired cartilage development and aggravated osteoarthritis Isoborneol restores METTL3 S-palmitoylation and improves osteoarthritic phenotypes in vivo S-palmitoylation drives METTL3 phase separation, translation, and protein stability METTL3, a key RNA N 6 -methyladenosine (m 6 A) methyltransferase, plays essential roles in cell fate regulation and tissue homeostasis, yet therapeutic strategies to enhance its activity remain unexplored. Here, we profile the S-palmitoylation landscape during embryonic stem cell differentiation and observe increased METTL3 S-palmitoylation at cysteine 376 during mesodermal commitment. This modification is catalyzed by ZDHHC24 and reversed by ABHD17A. METTL3 C376S mice exhibit cartilage defects and exacerbated osteoarthritis (OA). Through AI-guided screening, we identify Isoborneol as a small molecule that enhances METTL3 S-palmitoylation by disrupting its interaction with ABHD17A. Isoborneol treatment alleviates joint degeneration and preserves cartilage integrity in OA models. Mechanistically, S-palmitoylation promotes METTL3 condensate formation in proximity to ribosomes, facilitating its cytoplasmic spatial compartmentalization. This condensate state suppresses chaperone-mediated autophagy, thereby enhancing METTL3 protein stability. Our findings reveal S-palmitoylation as a regulatory mechanism governing METTL3 localization and turnover and establish a pharmacological strategy for restoring METTL3 activity in OA.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: